Could a heart drug tame aneurysms? new study investigates
NCT ID NCT06081153
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether evolocumab, a drug that lowers 'bad' cholesterol, changes the cells in the wall of an abdominal aortic aneurysm. About 44 people scheduled for aneurysm repair will receive either the drug or a placebo before surgery. Researchers will then compare the tissue removed during surgery to see if the drug reduces inflammation or other harmful cell activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL AORTIC ANEURYSM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves replace CT scans for aortic aneurysm monitoring?
- Can a stent-graft keep aortic aneurysms in check for years? a long-term follow-up study aims to find out.
- Aneurysm repair may stiffen arteries — a study asks what that means for the heart
- Rehab after aneurysm surgery: could a 3-Week program boost heart and lung fitness?
- Nerve block may offer safer pain relief after major aortic surgery
- New device aims to seal aortic aneurysms without open surgery